NN1213 / Novo Nordisk - LARVOL DELTA

A Study on How NNC0174-1213 Works in People With Overweight or Obesity. (clinicaltrials.gov) - P1 | N=178 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed | Trial primary completion date: Mar 2026 ➔ Jul 2026

Trial completion • Trial primary completion date • Genetic Disorders • Obesity

Beyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs. (PubMed, Pharmacol Res) - "Recent advances in peptide engineering, lipidation, and reversible albumin binding have enabled the development of long-acting amylin-based agents, including cagrilintide, eloralintide, petrelintide and NN1213. We place particular emphasis on the tolerability profile of this drug class and discuss how receptor pharmacology, hindbrain and parabrachial circuitry, species differences, and pharmacokinetic exposure may shape nausea, malaise, and emesis. Understanding how amylin-based therapies dissociate weight-loss efficacy from gastrointestinal intolerance may guide the rational design of next-generation anti-obesity drugs with improved clinical utility."

Journal • Review • Genetic Disorders • Metabolic Disorders • Obesity

In diet-induced obese rats, amylin receptor selective drug candidates lead to similar changes in fat mass and fat free mass loss than drug candidates activating both amylin and calcitonin receptors (ECO 2026) - "Studies in rats have shown a fat free mass (FFM) preserving effect of AS compared to the GLP-1 receptor agonist semaglutide or cagrilintide (NS), suggesting improved quality of weight loss...Rats were treated once daily for 20 days (subcutaneous injection) with vehicle, cagrilintide (NS), Compound 48 (WO2022/129254) (AS), GUBAmy (NS), NN1213 (AS), eloralintide (AS/NS) or petrelintide (NS) or with semaglutide... At a matched weight loss, the AMYR agonists tested resulted in similar fat mass and fat free mass changes as semaglutide. AS drug candidates had no preserving effect on fat free mass over NS drug candidates. Conflicts of Interest & Funding: Rune E Kuhre, David H Ipsen, Jesper F Lau, Thomas Kruse, Anna Secher and Kirsten Raun are employed by Novo Nordisk A/S"

Preclinical • Obesity

The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels (ADA 2025) - "Cagrilintide and eloralintide are both AMYR and CTR agonists whereas NN1213 is a selective AMYRs agonist that also decreases body weight in rats."

Preclinical • Metabolic Disorders • Obesity

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=353 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Metastases • Trial completion • Breast Cancer • Castration-Resistant Prostate Cancer • Colorectal Cancer • Genito-urinary Cancer • Hepatology • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

NCI-2013-02103: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (clinicaltrials.gov) - P1/2 | N=75 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

IO biomarker • Trial completion date • Trial primary completion date • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor • BCL2 • PTEN

A Study on How NNC0174-1213 Works in People With Overweight or Obesity. (clinicaltrials.gov) - P1 | N=177 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P1 | N=31 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2024 ➔ Mar 2025 | Trial primary completion date: Nov 2024 ➔ Mar 2025

Metastases • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

VNC-152-101: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=110 | Completed | Sponsor: Vincerx Pharma, Inc. | Active, not recruiting ➔ Completed

Combination therapy • Metastases • Monotherapy • Trial completion • Oncology • MYC

Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) (clinicaltrials.gov) - P2 | N=28 | Completed | Sponsor: Yonsei University | N=18 ➔ 28

Enrollment change • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=78 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Metastases • Trial completion date • Trial primary completion date • Colorectal Cancer • Cutaneous Melanoma • Genito-urinary Cancer • Melanoma • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • CD4 • CD8 • CTAG1B • FGF • HGF • MLANA

Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2 | N=21 | Completed | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Completed

Metastases • Surgery • Trial completion • CNS Tumor • Endocrine Cancer • Oncology • Solid Tumor

A Study on How NNC0174-1213 Works in People With Overweight or Obesity. (clinicaltrials.gov) - P1 | N=177 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors (clinicaltrials.gov) - P=N/A | N=333580 | Completed | Sponsor: Boehringer Ingelheim | N=99000 ➔ 333580

Enrollment change • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Hepatology • Infectious Disease • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (clinicaltrials.gov) - P=N/A | N=100000 | Recruiting | Sponsor: University of California, San Francisco | Trial completion date: Dec 2025 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

Physical Activity and Sedentary Behavior Change; Impact on Lifestyle (clinicaltrials.gov) - P=N/A | N=308 | Completed | Sponsor: University of Pittsburgh | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders

Dopamine and Motor Learning in Cerebral Palsy (clinicaltrials.gov) - P=N/A | N=28 | Completed | Sponsor: National Institutes of Health Clinical Center (CC) | Recruiting ➔ Completed | N=120 ➔ 28 | Trial completion date: May 2025 ➔ Nov 2024

Enrollment change • Trial completion • Trial completion date • Cerebral Palsy • CNS Disorders • BDNF • COMT • DRD2

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation (clinicaltrials.gov) - P3 | N=112 | Completed | Sponsor: Suleyman Demirel University | Active, not recruiting ➔ Completed

Trial completion • Atrial Fibrillation • Cardiovascular

Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa (clinicaltrials.gov) - P=N/A | N=7350 | Active, not recruiting | Sponsor: Oslo University Hospital | N=1350 ➔ 7350 | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Enrollment change • Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

IO biomarker • Surgery • Trial completion date • Trial primary completion date • Leiomyosarcoma • Liposarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • PD-L1